REGULATORY

• MHLW to Exclude High School-Age and Younger from OTC-Like Drug Charge: Official
  April 23, 2026

• Japan, Singapore to Share GMP Inspection Results under Cooperation Pact
  April 23, 2026

• MHLW Orders Label Revisions for Remicade, Enbrel, Bavencio, and More Drugs
  April 22, 2026

• Extra Charges Likely for OTC-Like Drugs to Treat Seasonal Conditions: Minister
  April 22, 2026

• Japan Panel to Review Boehringer’s IPF Drug, Moderna COVID Shot on April 27
  April 21, 2026

• Ferring Gene Therapy, Fujifilm Cell Product Inch Closer to Approval
  April 21, 2026

• Japan Launches Panel to Promote Radiopharmaceuticals
  April 21, 2026

• LDP Project Team to Seek Patent-Period Price Maintenance in Growth Strategy Proposal
  April 21, 2026

• Zepbound’s OSA Indication Up for Panel Review on April 24
  April 20, 2026

• Japan Sees No Need to Prioritize Naphtha Supply for Medical Use, METI Says
  April 20, 2026

• Minister Noncommittal on Drug Price Measures amid Middle East Crisis
  April 20, 2026

• LDP Pharma Project Team to Compile Roadmap Proposals after Industry Hearings
  April 17, 2026

• DPJ Leader to Urge Drug Price Hikes, “Freeze” on Off-Year Revisions
  April 17, 2026

• War-Linked Supply Impact Cases Climb to 34 as Japan Steps Up Response
  April 17, 2026

• Meiji Pharma Chair Prods Drug Price Hikes as War Drives Up Costs: Diet
  April 17, 2026

• Japan Eases Documentation Requirements for Excipients Listed in Foreign Pharmacopoeias
  April 17, 2026

• Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
  April 16, 2026

• MHLW to Set Criteria for Exemptions under OTC-Like Drug Charge Scheme
  April 16, 2026

• MHLW Taps Kawabata to Lead Drug Discovery Support Office
  April 15, 2026

• MHLW Reviewing EMIS Data on Petro-Product Supply to Medical Institutions
  April 15, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »